Related Experiment Video
Updated: Feb 10, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Update on signal inhibitors in chronic lymphocytic leukemia
1The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
The last decade has seen major progress in our understanding of the pathobiology of chronic lymphocytic leukemia (CLL) and the identification of potential new therapeutic targets. As a result, researchers have developed novel targeted therapies, several of which are already approved and many of which are in advanced stages of clinical development. These new agents are much less toxic than chemoimmunotherapy and may be preferred for their superior efficacy in patients with certain high-risk features, such as del(17p). The place of these therapies in CLL management is becoming better defined, and they are gradually replacing traditional forms of chemoimmunotherapy. This review provides an update on the clinical data regarding various signal transduction inhibitors in CLL.
Insights
New targeted therapies are improving chronic lymphocytic leukemia (CLL) treatment, offering superior efficacy and reduced toxicity compared to traditional chemoimmunotherapy, especially for high-risk patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Significant advancements in understanding chronic lymphocytic leukemia (CLL) pathobiology.
- Identification of novel therapeutic targets driving new treatment strategies.
Purpose of the Study:
- To review clinical data on signal transduction inhibitors in CLL.
- To provide an update on emerging targeted therapies for CLL management.
Main Methods:
- Review of clinical data for signal transduction inhibitors.
- Analysis of approved and investigational targeted therapies.
Main Results:
- Novel targeted therapies demonstrate improved efficacy and reduced toxicity over chemoimmunotherapy.
- These agents are particularly beneficial for high-risk CLL patients, including those with del(17p).
Conclusions:
- Targeted therapies are becoming the standard of care in CLL, gradually replacing chemoimmunotherapy.
- The role of signal transduction inhibitors in CLL management is increasingly well-defined.
More Related Videos
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Endocrine Signaling
Bacterial Signaling
Yeast Signaling
What is Cell Signaling?
Paracrine Signaling

